165 related articles for article (PubMed ID: 37755671)
1. Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older.
Neveu D; Mallett Moore T; Zambrano B; Chen A; Kürzinger ML; Marcelon L; Singh Dhingra M
Infect Dis Ther; 2023 Oct; 12(10):2367-2386. PubMed ID: 37755671
[TBL] [Abstract][Full Text] [Related]
2. Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial.
Knuf M; Rämet M; Breinholt Stærke N; Bertrand-Gerentes I; Thollot Y; B'Chir S; Arroum H; Oster P
Hum Vaccin Immunother; 2022 Nov; 18(5):2052657. PubMed ID: 35445641
[TBL] [Abstract][Full Text] [Related]
3. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States.
Chang LJ; Hedrick J; Christensen S; Pan J; Jordanov E; Dhingra MS
Vaccine; 2020 Apr; 38(19):3560-3569. PubMed ID: 32209248
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
Zambrano B; Peterson J; Deseda C; Julien K; Spiegel CA; Seyler C; Simon M; Hoki R; Anderson M; Brabec B; Áñez G; Shi J; Pan J; Hagenbach A; Von Barbier D; Varghese K; Jordanov E; Dhingra MS
Pediatr Res; 2023 Sep; 94(3):1035-1043. PubMed ID: 36899125
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)
van der Vliet D; Vesikari T; Sandner B; Martinón-Torres F; Muzsay G; Forsten A; Adelt T; Diaz Gonzalez C; Simko R; B'Chir S; Neveu D; Jordanov E; Dhingra MS
Epidemiol Infect; 2021 Feb; 149():e50. PubMed ID: 33541457
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study.
Áñez G; Hedrick J; Simon MW; Christensen S; Jeanfreau R; Yau E; Pan J; Jordanov E; Dhingra MS
Hum Vaccin Immunother; 2020 Jun; 16(6):1292-1298. PubMed ID: 32209015
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.
Matsuoka O; Ujiie M; Kikuchi H; Otake S; Chansinghakul D; Inoue T; Varghese K; Sirisuphmitr N; Hashiguchi T; Zambrano B; Nakama T; Frago C; Jordanov E; Dhingra MS
Jpn J Infect Dis; 2023 May; 76(3):174-182. PubMed ID: 36724939
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study.
Robertson CA; Jacqmein J; Selmani A; Galarza K; Oster P
Hum Vaccin Immunother; 2023 Dec; 19(1):2160600. PubMed ID: 36632042
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study.
Dhingra MS; Peterson J; Hedrick J; Pan J; Neveu D; Jordanov E
Vaccine; 2020 Jul; 38(33):5194-5201. PubMed ID: 32565344
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study.
Vesikari T; Borrow R; Forsten A; Findlow H; Dhingra MS; Jordanov E
Hum Vaccin Immunother; 2020 Jun; 16(6):1306-1312. PubMed ID: 32233959
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study.
Piazza FM; Virta M; Paassilta M; Ukkonen B; Ahonen A; Esteves-Jaramillo A; Forsten A; Seppa I; Ding J; Neveu D; Jordanov E; Dhingra MS
Hum Vaccin Immunother; 2022 Dec; 18(1):1-10. PubMed ID: 34085900
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study.
Kirstein J; Pina M; Pan J; Jordanov E; Dhingra MS
Hum Vaccin Immunother; 2020 Jun; 16(6):1299-1305. PubMed ID: 32233961
[TBL] [Abstract][Full Text] [Related]
13. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS
Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study.
Esteves-Jaramillo A; Koehler T; Jeanfreau R; Neveu D; Jordanov E; Singh Dhingra M
Vaccine; 2020 Jun; 38(28):4405-4411. PubMed ID: 32387012
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion.
Ricci S; Azzari C; Amodio E; Castiglia P
Expert Rev Vaccines; 2023; 22(1):447-456. PubMed ID: 37144288
[TBL] [Abstract][Full Text] [Related]
16. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT.
Martinón-Torres F; Bertrand-Gerentes I; Oster P
Expert Rev Vaccines; 2021 Sep; 20(9):1123-1146. PubMed ID: 34365870
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II study.
Cornish MJ; Hedrick JA; Gabrielsen AA; Johnson AD; Miriam Pina L; Rehm C; Pan J; Neveu D; Da Costa X; Jordanov E; Dhingra MS
Vaccine; 2022 Mar; 40(10):1421-1438. PubMed ID: 35144847
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM
Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209
[TBL] [Abstract][Full Text] [Related]
19. Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults.
Deeks ED
BioDrugs; 2010 Oct; 24(5):287-97. PubMed ID: 20795751
[TBL] [Abstract][Full Text] [Related]
20. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
